Glow 70mg — 45 Sprays

Product classification

Glow 70mg — 45 Sprays is a three-component research compound blend. It is not a single molecular entity and does not have a single molecular formula, molecular weight, or CAS number. It is classified as a multi-component research formulation for Research Use Only.

Constituent components

GHK-Cu (glycyl-L-histidyl-L-lysine copper(II) complex) — CAS 89030-95-5; molecular formula C₁₄H₂₂CuN₆O₄; molecular weight ~401.91 g/mol. A naturally occurring copper-binding metallopeptide complex coordinated through an ATCUN-motif geometry. Analytically distinct from uncomplexed GHK (CAS 49557-75-7, MW ~340.38 g/mol); characterization must confirm both peptide sequence and copper association.

BPC-157 (Body Protection Compound-157) — CAS 137525-51-0; molecular formula C₆₂H₉₈N₁₆O₂₂; molecular weight ~1,419.53 g/mol. A synthetic pentadecapeptide (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a partial sequence of a gastric protein.

TB-500 (thymosin beta-4 synthetic fragment) — CAS 885340-08-9; molecular formula C₂₁₂H₃₅₀N₅₆O₇₈S; molecular weight ~4,963.51 g/mol. A synthetic 43-amino-acid compound corresponding to the thymosin beta-4 sequence, associated with G-actin sequestration via the LKKTET actin-binding motif. Distinct from the full-length thymosin beta-4 protein (CAS 77591-33-4).

Component quantities

The individual quantities of GHK-Cu, BPC-157, and TB-500 within the 70mg total are specified in Longevia Research product documentation. Researchers should consult available analytical documentation for component-specific information.

Total stated formulation quantity: 70mg combined across all three components.

Product content: 70mg per bottle; 45 sprays per bottle.

Physical form: Liquid research spray.

Purity: Research-grade.

Analytical documentation

A batch-specific Certificate of Analysis is available on the Longevia Research website, covering product identity, purity, and lot traceability.

Research-use classification

Research Use Only. No component of this formulation — individually or in combination — is approved for human or veterinary use. Not intended for administration to humans or animals.

Component research profiles and molecular targets

The three Glow components engage distinct molecular targets and biological pathways; there is no single unified molecular target for the formulation as a whole. GHK-Cu does not bind a single confirmed receptor — research has proposed and investigated interactions with extracellular matrix-associated systems including MMP/TIMP regulation in fibroblast cell cultures, copper-dependent enzymatic systems such as lysyl oxidase and superoxide dismutase, and broad transcriptional regulatory networks characterized in microarray studies of human cell lines, though no definitive primary mechanism has been established. BPC-157's molecular mechanism has not been established at the receptor level; proposed interactions from animal model and cell-based research include nitric oxide system modulation, VEGF and EGF receptor-associated signaling, and cellular signaling cascades relevant to angiogenesis-associated processes. TB-500's primary characterized molecular interaction is G-actin sequestration through its LKKTET actin-binding motif, regulating the equilibrium between monomeric G-actin and filamentous F-actin and influencing cytoskeletal organization and cellular migration behavior in experimental systems; additional proposed mechanisms include interactions with integrins and extracellular matrix components in preclinical research.

Key research areas by component

GHK-Cu has an extensive preclinical literature spanning in-vitro fibroblast cell culture studies of collagen-related gene expression and MMP/TIMP regulation, microarray gene-expression analyses in human cell lines, rodent wound biology model studies, and small human observational studies involving topical preparations — the latter differing substantially in design and rigor from controlled clinical trials. BPC-157 has a substantial rodent animal model literature covering gastrointestinal tissue biology, angiogenesis-associated measures, musculoskeletal tissue-related parameters, and cellular signaling observations across multiple tissue models; human clinical research is limited and no approved therapeutic use exists. TB-500 has been studied in animal models examining wound-related biological parameters, cardiac tissue research in ischemia models, and actin dynamics in cell-based systems; the synthetic TB-500 fragment specifically has a more limited research base than the endogenous thymosin beta-4 protein in some contexts, and no approved human therapeutic use exists.

Formulation-level considerations

No published research has systematically characterized the combined molecular interactions of GHK-Cu, BPC-157, and TB-500 as a co-formulated blend at the receptor or biochemical level, and no controlled clinical research has examined the specific Glow formulation in human subjects. Researchers should approach the scientific evidence base as consisting exclusively of independent single-component preclinical and experimental data and should not attribute findings from single-component studies to the multi-component preparation without specific combination study support. Evidence for individual components does not establish efficacy or safety for the combined Glow formulation. Note that KLOW 80mg — also available from Longevia Research — shares these three components and adds KPV (10mg) as a fourth constituent; researchers comparing the two formulations should account for the compositional difference when interpreting experimental results.

Quality in a multi-component peptide research preparation requires analytical approaches appropriate to each distinct constituent compound, as well as to the formulation as a whole. The Glow 70mg blend contains three chemically distinct research peptides — each with its own amino acid sequence, molecular identity, and analytical requirements — that must be individually characterized in addition to characterization of the combined preparation.

Component identity verification for each peptide: Analytical characterization of the Glow formulation requires confirmation of the identity of all three components: GHK-Cu (metallopeptide complex, C₁₄H₂₂CuN₆O₄, MW ~401.91 g/mol), BPC-157 (pentadecapeptide, C₆₂H₉₈N₁₆O₂₂, MW ~1,419.53 g/mol), and TB-500 (thymosin beta-4 synthetic fragment, C₂₁₂H₃₅₀N₅₆O₇₈S, MW ~4,963.51 g/mol). The significant difference in molecular weight between the three components — spanning from ~402 to ~4,964 g/mol — means that chromatographic and mass spectrometric methods must be suited to the full mass range of the preparation.

Mass spectrometric characterization: Electrospray ionization mass spectrometry and related techniques capable of resolving species across the molecular weight range spanned by these three components — from a metallopeptide under 500 g/mol to a synthetic thymosin fragment approaching 5,000 g/mol — provide the primary analytical tool for confirming component identity. Multi-analyte mass spectrometric workflows may be required to cover the full composition of the blend.

Chromatographic resolution and purity assessment: High-performance liquid chromatography (HPLC) provides analytical separation of the blend's components from co-eluting impurities and from one another, enabling quantitative purity assessment at the individual component level. The analytical challenge of resolving three peptides of substantially different molecular weights and physicochemical properties in a single chromatographic workflow is relevant to researchers evaluating the analytical documentation for this formulation.

GHK-Cu-specific considerations: As a metallopeptide complex, GHK-Cu requires analytical characterization that addresses both the peptide sequence (Gly-His-Lys) and the copper association, confirming the presence of the copper-bound form (C₁₄H₂₂CuN₆O₄) rather than the free GHK tripeptide (C₁₄H₂₄N₆O₄). Analytical methods should be capable of distinguishing these chemically distinct forms.

Batch traceability and formulation documentation: For a multi-component research blend, batch-specific documentation at the component level provides the traceability required for reproducible experimental design. Researchers should confirm that available analytical documentation for the Glow preparation addresses each component's identity and purity at the individual compound level, not only the total formulation.

Spray format analytical considerations: Research peptide blends supplied in spray format require appropriate characterization of the formulated preparation, including evidence supporting homogeneity of component distribution and stability within the preparation. Researchers should consider whether available analytical documentation addresses formulation-specific parameters relevant to the spray format.

Longevia Research is committed to supplying research compounds that support rigorous scientific inquiry. Researchers are encouraged to review available analytical documentation for this product prior to incorporating it into laboratory workflows.

Glow 70mg — 45 Sprays is supplied by Longevia Research strictly for research and laboratory use only. No component of this product — GHK-Cu, BPC-157, or TB-500 — is approved by the FDA or any global regulatory authority for human consumption, veterinary use, or therapeutic application. The formulation as a whole is not a drug, dietary supplement, food, or cosmetic, and it is not manufactured, labeled, or sold as any of these under any applicable regulatory framework.

No claims made regarding Glow 70mg — 45 Sprays, or its constituent components, on this website are intended to diagnose, treat, cure, or prevent any disease or medical condition in humans or animals. The research findings summarized on this page arise from preclinical animal studies, cell-based experiments, biochemical investigations, and limited observational human research conducted on individual components. These findings do not establish human efficacy or safety for any application — including wound healing, tissue regeneration, skin biology, anti-aging, or recovery — and they do not constitute regulatory approval, clinical validation, or authorization for personal or therapeutic use of any kind.

Research conducted on individual components (GHK-Cu, BPC-157, or TB-500) does not automatically establish safety, efficacy, or regulatory approval for the complete Glow formulation. The three components have distinct scientific identities and independent research profiles; their combination in a single preparation has not been clinically validated.

This product is sold exclusively to qualified researchers, laboratories, and scientific institutions for in-vitro and non-clinical laboratory research purposes. It is not intended for personal use, self-administration, topical application in any clinical or consumer context, injection, resale for human consumption, or any application outside of a controlled research environment. Purchasers are responsible for ensuring that the acquisition, possession, handling, storage, use, and disposal of this compound are conducted in full compliance with all applicable local, state, federal, and international laws and institutional policies governing research chemicals.

By purchasing Glow 70mg — 45 Sprays from Longevia Research, the buyer confirms they are acquiring the product for legitimate scientific research purposes, agrees to handle and store it in accordance with applicable laboratory safety standards, and assumes full responsibility for compliance with all laws and regulations governing the purchase and use of research chemicals in their jurisdiction.